NIDA Avenir Program: Fundamental Mechanistic Research in Addiction Science

Avenir, the French word for "future," reflects NIDA's commitment to developing the next generation of leaders in addiction science. Since 2015, the Avenir Program has supported exceptionally creative early stage investigators (ESIs) in launching innovative research programs. NIDA is now expanding this program to support bold mechanistic research across a broader range of addiction science, including genetic, epigenetic, molecular, cellular, circuit, chemical, pharmacological, behavioral, and cognitive processes relevant to Substance Use Disorders (SUDs). This initiative is intended to catalyze high-risk, high-reward research and attract outstanding new investigators, including those from outside the addiction field. Applications proposing novel, unconventional, or interdisciplinary wet-lab and/or data science approaches to advance understanding of the mechanisms underlying SUDs are encouraged. The Avenir Program is designed for ESIs who may lack the preliminary data needed for an R01 application but propose high-impact research and show strong potential to become future leaders in fundamental mechanistic addiction science. Grant authorities that allow NIDA to forecast this opportunity are 42 U.S.C. §§ 241 and 284.

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

The following considerations will be used in determining projects to be funded: (1) Scientific and technical merit; (2) the feasibility of the research; (3) potential contribution to the national drug abuse problem; and (4) relevance to NIDA priorities. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technology.